N-Acetyltransferase 2 Genotype-Related Efficacy of Sulfasalazine in Patients with Rheumatoid Arthritis

Pharmaceutical Research

Volumn 21, Issue 2, 2004, Pages 324-329

  Kumagai, Shunichi ^a   Komada, Fusao ^b   Kita, Tomoko ^c,d   Morinobu, Akio ^a   Ozaki, Shoichi ^d,h   Ishida, Hiroshi ^e   Sano, Hajime ^f,i   Matsubara, Tsukasa ^g   Okumura, Katsuhiko ^c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JOSAI UNIVERSITY   (Japan)

^c KOBE UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e UTANO NATIONAL HOSPITAL   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g Matsubara Mayflower Clinic   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Genotype; N acetyltransferase 2; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; AZULFIZINE; DRUG METABOLITE; N ACETYLSULFAPYRIDINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ADULT; AGED; ALLELE; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; VOMITING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SULFASALAZINE; TIME FACTORS;

EID: 1242314682     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000016246.84974.ec     Document Type: Article

References (31)

1. D. M. van der Heijde, P. L. van Riel, I. H. Nuver-Zwart, F. W. Gribnau, and L: B. van de Putte. Effect of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036-1038 (1989).
2. U. Klotz. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokinet. 10:285-302 (1985).
3. K. M. Das and R. Dubin. Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokinet. 1:406-425 (1976).
4. G. Carlin, R. Djursater, and G. Smedegard. Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonuclear leukocytes. Pharmacol. Toxicol. 65:121-127 (1989).
5. M. Fujiwara, K. Mitsui, and I. Yamamoto. Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites. Jpn. J. Pharmacol. 54:121-131 (1990).
6. K. M. Das, M. A. Eastwood, J. P. A. McManus, and W. Sircus. The metabolism of salicylazosulphapyridine in ulcerative colitis. Gut 14:631-641 (1973).
7. A. K. Azad Khan, D. T. Howes, J. Piris, and S. C. Truelove. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 21:232-240 (1980).
8. K. M. Das, M. A. Eastwood, J. P. A. McManus, and W. Sircus. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N. Engl. J. Med. 289:491-495 (1973).
9. H. Schroder and D. A. P. Evans. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 13:278-284 (1972).
10. D. A. P. Evans. N-Acetyltransferase. Pharmacol. Ther. 42:157-234 (1989).
11. C. J. Laversuch, D. A. Collins, P. J. Charles, and B. E. Bourke. Sulphasalazine autoimmune abnormalities in patients with rheumatic disease. Br. J. Rheumatol. 34:435-439 (1995).
12. G. D. Kitas, M. Farr, L. Waterhouse, and P. A. Bacon. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand. J. Rheumatol. 21:220-225 (1992).
13. T. Pullar, J. A. Hunter, and H. A. Capell. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann. Rheum. Dis. 44:831-837 (1985).
14. D. E. Bax, M. S. Greaves, and R. S. Amos. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Br. J. Rheumatol. 25:282-284 (1986).
15. C. P. Rains, S. Noble, and D. Faulds. Sulfasalazine: A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 50:137-156 (1995).
16. A. J. Taggart, B. J. McDermott, and S. D. Roberts. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis. Clin. Pharmacokinet. 23:311-320 (1992).
17. S. Ohsako and T. Deguchi. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J. Biol. Chem. 265:4630-4634 (1990).
18. M. Abe, T. Deguchi, and T. Suzuki. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem. Biophys. Res. Commun. 191:811-816 (1993).
19. K. Okumura, T. Kita, S. Chikazawa, F. Komada, S. Iwakawa, and Y. Tanigawara. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin. Pharmacol. Ther. 61:509-517 (1997).
20. T. Kita, Y. Tanigawara, S. Chikazawa, H. Hatanaka, T. Sakaeda, F. Komada, S. Iwakawa, and K. Okumura. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Bio. Pharm. Bull. 24:544-549 (2001).
21. Y. Tanigawara, T. Kita, N. Aoyama, M. Gobara, F. Komada, T. Sakai, M. Kasuga, H. Hatanaka, T. Sakaeda, and K. Okumura. N-Acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol. Pharm. Bull. 25:1058-1062 (2002).
22. T. Kita, T. Sakaeda, S. Adachi, T. Sakai, N. Aoyama, H. Hatanaka, M. Kasuga, and K. Okumura. N-Acetyltansferase 2 genotype correlates with sulfasarazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biol. Pharm. Bull. 24:1176-1180 (2001).
23. D. T. Felson, J. J. Anderson, M. Boers, C. Bombardier, D. Furst, C. Goldsmith, L. M. Katz, R. Jr. Lightfoot, H. Paulus, and V. Strand. American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38:727-735 (1995).
24. T. Deguchi, M. Mashimo, and T. Suzuki. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 265:12757-12760 (1990).
25. M. Mashimo, T. Suzuki, M. Abe, and T. Deguchi. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum. Genet. 90:139-143 (1992).
26. C. Maslinski and A. Fogel. Catabolism of histamine. In B. Uvans (ed.), Handbook of Experimental Pharmacology: Histamine and Histamine Antagonists, Berlin: Springer-Verlag, 1991, pp. 165-189.
27. Y. Endo. Elevation of histamine levels in rat and mouse tissue by deacetylation of administered N-acetylhistamine. Eur. J. Pharmacol. 60:299-305 (1979).
28. H. Tabor, A. H. Mehler, and E. R. Stadtman. The enzymatic acetylation of amines. J. Biol. Chem. 204:127-138 (1953).
29. A. Pawlik, L. Ostanek, I. Brzosko, B. Gawroska-Szklarz, M. Brzosko, and E. Dabrowska-Zamojcin. Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 72:319-325 (2002).
30. E. Uchida, K. Kai, S. Kobayashi, K. Oguchi, Y. Miyazaki, and H. Yasuhara. A study of pharmacokinetics and safety of salazosulfapyridine enteric coated tablet (PJ-306) in healthy Japanese subjects. Jpn. J. Pharmacol. Ther. 21:377-389 (1990).
31. T. Pullar. Adverse effects of sulphasalazine. Adverse Drug React. Toxicol. Rev. 11:93-109 (1992).